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Abstract
Lead, which is widely used in industry, is a common element found in low concentrations in the Earth’s crust.
Implementations to reduce environmental lead concentrations have resulted in a considerable reduction of lead
levels in the environment (air) and a sustained reduction in the blood lead levels of the average citizen. However,
people are still being exposed to lead through a variety of routes in everyday commodities.
Lead causes health problems such as toxicity of the liver, kidneys, hematopoietic system, and nervous system. Having
a carcinogenic risk as well, the IARC classifies inorganic lead compounds as probably carcinogenic to humans (Group
2A). Occupational lead poisonings have decreased due to the efforts to reduce the lead concentrations in the working
environment. In contrast, health hazards associated with long-term environmental exposure to low concentrations of
lead have been reported steadily. In particular, chronic exposure to low concentrations of lead has been reported to
induce cognitive behavioral disturbances in children.
It is almost impossible to remove lead completely from the human body, and it is not easy to treat health hazards
due to lead exposure. Therefore, reduction and prevention of lead exposure are very important. We reviewed the
toxicity and health hazards, monitoring and evaluation, and management of lead exposure.
Keywords: Antioxidants, Chelation, Environmental, Exposure, Lead
Background
Lead is a common element found in low concentrations
in the Earth’s crust. It is widely used in industry, particu-
larly in products such as construction materials, paint,
batteries, and piping. Lead causes health problems such
as toxicity of the liver, kidneys, hematopoietic system,
and nervous system. Having a carcinogenic risk as well,
the IARC classifies inorganic lead compounds as prob-
ably carcinogenic to humans (Group 2A) [1]. Children,
in particular, are at risk of developing cognitive behav-
ioral function problems, even when exposed to low
concentrations [2].
During the 1970’s and 80’s, concern over lead related
health problems led to the implementation of policies,
such as the introduction of unleaded gasoline and a
ban on using lead-based paint. This has resulted in a
considerable reduction of lead levels in the environment
(air) and a sustained reduction in the blood lead levels
of the average citizen [3]. However, people are still being
exposed to lead through a variety of routes, such as
secondhand exposure to pollution in the workplace,
everyday household products, children’s toys, and in
everyday commodities [4].
There has been much research conducted on the
occupational and environmental exposure to lead, as
well as its health impact, treatment, and management.
Recently, research has been conducted on the manage-
ment of low-level lead exposure. This study sought to
examine and organize the results of recent research on
the diagnosis and health impact of lead, as well as its
treatment and management.
Mechanism of toxicity
Toxicity is known to occur through lead-induced oxida-
tive stress [5]. The mechanism of lead-induced oxidative
stress has been described as the depletion of antioxida-
tive reserves and the increased generation of reactive
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oxygen species (ROS), such as hydroperoxides [6]. Ninety
percent of glutathione (GSH) in the cell exists in reduced
form and 10 % in oxidative form, and it typically acts as
an antioxidant defense mechanism. Reacting to ROS,
GSH stabilizes ROS, and after being converted (oxidizing)
to glutathione disulfide (GSSG), it is reduced back to GSH
by glutathione reductase (GR). Lead inactivates GSH by
binding to GSH’s sulfhydryl group, which causes GSH
replenishment to become inefficient, thereby increasing
oxidative stress [7]. In addition, lead further reduces gluta-
thione levels by blocking the activity of enzymes such as
δ-aminolevulinic acid dehydratase (ALAD), glutathione
reductase (GR), glutathione peroxidase, and glutathione-
S-transferase [8]. Lead destabilizes the cellular membrane
through lipid peroxidation, which can lead to hemolytic
anemia [9]. The collective action of various such mecha-
nisms makes the cell vulnerable to oxidative stress,
causing cell death.
Toxicity also arises from lead replacing divalent cations,
which are necessary for cellular activity. The main mech-
anism causing neurological abnormalities is the ionic
mechanism that substitutes lead for calcium ions, allow-
ing it to pass through the blood-brain barrier [10]. By
penetrating the blood-brain barrier, lead accumulates in
astroglial cells, disrupting myelin sheath formation. Even
in very small concentrations, lead affects neural excitation
and memory-related neurotransmitter activity [11].
Toxicity of lead
Lead toxicity can cause acute or chronic health impacts.
Though it can affect various organs in the body, it
mainly leads to toxicity of the nervous, hematopoietic,
cardiovascular, and other systems. In addition, recent
studies have been reporting that lead is carcinogenic.
While acute toxicity is uncommon, it occurs mainly due
to occupational exposure, and in severe cases, it may
cause death. Chronic toxicity occurs at relatively low
levels, and there are quite frequent reports of the occur-
rence of negative health impacts, particularly in children,
including the occurrence of neurobehavioral development
abnormalities, at even lower blood lead levels.
Neurologic toxicity
The nervous system is the organ system most vulnerable
to lead-induced toxicity [12]. While problems can occur
in both the central and peripheral nervous systems,
the peripheral nervous system is mainly affected in
adults, whereas in children, the central nervous system
is primarily affected [13]. When the impact on the central
nervous system is severe, it manifests as encephalopathy.
In relatively minor cases, symptoms such as headaches,
irritability, muscular tremors, and loss of memory occur,
whereas severe cases can result in delirium, convul-
sions, or coma [14]. Because their nervous system is
still developing, children can be particularly vulnerable.
Studies have reported that low levels of chronic exposure
still have a negative effect on neurobehavioral develop-
ment, such as lowered IQ and ADHD-like symptoms [2].
Resulting in demyelination, peripheral nervous system
abnormalities frequently take the form of a peripheral
neuropathy that invades the extensor motor nerves [15].
Hematologic toxicity
Lead causes anemia by dose-dependently blocking the
activity of ferrochelatase, aminolevulinic acid synthetase
(ALAS), and ALAD, three important enzymes related to
the synthesis of heme. Among these, ALAD is the most
markedly affected, and is therefore used as a clinical
marker for lead poisoning. When ALAD is inhibited,
aminolevulinic acid accumulates, and blood lead levels
of 10 μg/dL and even lower begin to be detected [16].
Exposure to high levels of lead can lead to acute hemolytic
anemia [17].
Cardiovascular toxicity
Lead raises the blood pressure, which increases the risk
of death from cardiovascular disease. Lead exposure
increases the frequency of high blood pressure, as well
as cerebrovascular and cardiovascular disease [18]. An
increase in blood lead levels has been shown to have a
significant correlation with cardiovascular disease-related
death [19]. Some findings have appeared to show a signifi-
cant degree of correlation between blood lead levels and
systolic and diastolic blood pressure [20]. There has been
a great deal of research conducted on the relationship
between low levels of lead exposure and blood pressure,
and while there is still much that is up for debate, recent
studies have found that low levels of lead exposure can
cause high blood pressure [21]. The mechanism by which
lead raises blood pressure is still not clearly understood.
While some studies claim an association with chronic
nephropathy [22], recent findings have suggested oxidative
stress as the mechanism [21].
Other toxicity
Some studies have found lead to be a cause of reproduct-
ive toxicity in both men and women. In men, it causes a
reduction in libido, infertility, as well as a reduction in
sperm count and vigor, while in women there is an
increase in the incidence of stillbirth and miscarriage [23].
Additionally, lead can cause a vitamin D deficiency by dis-
rupting the conversion of vitamin D into its biologically
active form, 1,25-dyhydroxyvitamin D [24].
Carcinogenicity
The International Agency for Research on Cancer (IARC)
deems inorganic lead to be probably carcinogenic to
humans (IARC Group 2A), based on sufficient evidence
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from animal testing and limited evidence with human
subjects [1]. Lead smelters, plumbers, battery recycling
smelters, pigment producers, and so on, are at risk to oc-
cupational exposure. Lead exposure is known to increase
the risk of lung, stomach, and bladder cancer. Organic
lead belongs to IARC Group 3, meaning that there is not
sufficient evidence to evaluate whether or not it causes
cancer in humans. However, a portion of organic lead can
be metabolized as ionic lead, and in such instances,
toxicity similar to that of inorganic lead can arise [1].
Symptoms and signs of lead exposure
Symptoms of lead poisoning take a variety of forms
based on the period of exposure and individual character-
istics, and depending on the circumstances, non-specific
or minor symptoms may appear, or there may even be
cases with no noticeable symptoms whatsoever. In cases
of chronic exposure, symptoms appear to become incre-
mentally more severe as the weeks pass, whereas in cases
of acute exposure, strong symptoms can suddenly appear.
The degree or type of symptoms that patients complain of
may differ depending on the form of the lead to which
they are exposed. As organic lead has a higher lipid
solubility compared with inorganic lead, its toxicity is
stronger and its symptoms are mainly related to the
central nervous system, such as insomnia, delirium, cogni-
tion problems, and tremors [25].
Symptoms manifest differently in adults than they do
in children. In adults, major symptoms include headach,
stomachach, memory loss, renal failure, sexual dysfunc-
tion, and reduced sensation in the limbs, and in the early
period, non-specific symptoms may manifest such as
depression, reduced appetite, intermittent stomachach,
nausea, diarrhea, and constipation [25]. While symp-
toms generally manifest when blood lead levels exceed
40 μg/dL in adults and 60 μg/dL in children, symptoms
may appear at different ranges depending on the individ-
ual’s characteristics [13]. Neuropsychological problems
like delayed reaction time, reduced concentration, reduced
neurotransmitter speed, and headaches first appear at
blood lead levels of 25–60 μg/dL, anemia appears at blood
lead levels of 50 μg/dL and over, colic in cases of 80 μg/dL
and over, and intracranial hypertension and delirium begin
to manifest when blood lead levels exceed 100 μg/dL,
along with wrist drop, foot drop, and encephalopathy. In
the case of children, neurological symptoms begin to
manifest when blood lead levels exceed 70 μg/dL [26].
There are almost no instances of cases without symptoms
once blood lead levels have exceeded 100 μg/dL, in either
adults or children.
Acute exposure
During acute poisoning, neurological symptoms may
occur such as pain, weakened muscle power, sensory
abnormalities, and occasionally brain inflammation, along
with digestive system-related symptoms such as stomach-
aches, nausea, vomiting, diarrhea, and constipation [27].
In instances where a large amount of lead has been
ingested through the digestive system in a short period of
time, the loss of a lot of water in the digestive system can
cause shock, hemolytic action occurs, and symptoms such
as anemia and hematuria may occur. In instances where
the kidneys are damaged, the amount of urine decreases;
individuals who showed symptoms of acute lead exposure
can also show symptoms similar to those of chronic lead
exposure [28].
Chronic exposure
In cases of chronic lead exposure, a variety of symptoms
may manifest, mainly in the digestive system, nervous
system, and neurological system. Neurological symptoms
arise from a strong exposure over a relatively short time
period. By contrast, digestive system symptoms generally
arise from long-term exposure. In cases of chronic ex-
posure over a long period of time, a variety of symptoms
may manifest, including anemia, fatigue, reduced limb
sensation, stomachache, nausea, vomiting, depression, and
reduced concentration and memory [29]. Chronic lead
poisoning may also manifest as a grey color in the skin or
a blue line in the gums, known as the Burton line [30].
Aside from these symptoms, an increase in optic neuritis-
induced scotoma and vision impairments may occur.
Lead exposure in pregnancy and children
Exposure of an embryo or fetus in utero to lead in-
creases the possibility of premature birth and low birth
weight [31]. As the body size of children is smaller than
that of adults and lead is more quickly absorbed, they
are more vulnerable to lead poisoning. Additionally,
because babies crawl on the floor and suck on various
objects, they are more readily exposed to lead. Common
symptoms occurring in children include a loss of appetite,
stomachache, vomiting, learning disabilities, behavioral
problems, and anemia, while in abnormally high levels
of lead exposure, symptoms of leukonychia striata are
observed [32].
Evaluation and diagnosis of lead exposure
Because the symptoms of lead poisoning do not appear
instantly, even after having been exposed to lead, it is not
easy to diagnose. Therefore, when lead poisoning is sus-
pected, basic information should be determined through a
medical interview that takes into consideration the symp-
toms reported by the patient, current medical history, and
the surrounding environment or diet that could be associ-
ated with lead exposure. After a basic medical interview
and examination, the lead concentrations are measured in
the blood, hair, urine, and saliva. After confirming the
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presence of lead poisoning, the most important priority
when observing progression is measuring the blood lead
levels. Besides lead concentration levels, a number of
other biomarkers are also measured during blood testing
along with the lead concentration in the bone or soft
tissue.
Lead concentration in the blood
Measuring blood lead levels is the most common method
used for confirming the presence of lead. Currently, the
blood lead level of a healthy adult who has not been
exposed to a large amount of lead is 25 μg/dL or lower
[33], and for children, the current threshold of 10 μg/dL
or lower was revised to 5 μg/dL or lower [34]. The thresh-
old for the occupational lead exposure group should
not exceed 30 μg/dL during random blood testing, and
NIOSH urged that the blood lead level for adults be
lowered to under 10 μg/dL [35]. Looking at the measured
blood lead levels of individuals exposed to lead chronic-
ally, levels of 30–80 μg/dL have been found in children
living in old houses painted with lead-based paint, 77–
104 μg/dL in pottery-glaze workers, 90–137 μg/dL in
individuals who consumed contaminated herbal medi-
cine, 109–139 μg/dL in indoor firing range instructors,
and up to 330 μg/dL in individuals who had drunk
juice from glazed pottery [36].
Lead concentration in bone
Lead is stored in two parts of the bone. Lead stored in
the bone’s surface can readily pass into the blood,
whereas lead stored in cortical bone is virtually immobi-
lized. Studies have reported that 40–70 % of lead in the
blood of adults originates from bones [37]. In the case of
mothers, as the physiology of bone reabsorption differs,
the percentage of lead in the blood that originates in the
bones varies from 10–88 %, while 80 % or greater of the
lead in the blood of fetuses and embryos is provided by
the mother [38]. Lead exposure reduces bone density in
adults, increasing the risk of osteoporosis [39].
Lead concentration in cortical bone can be measured
through X-ray fluoroscopy (XRF). While lead in the blood
does not reflect the degree to which lead has accumulated
in the body at the time of the blood test [40], lead in
cortical bone is meaningful because it can reflect the
degree of long-term lead exposure and accumulation.
Ethylenediaminetetraacetic acid (EDTA) mobilization
testing and bone XRF are known to be the most sen-
sitive techniques for determining the degree of lead
accumulation [41].
Lead concentration in soft tissue
Lead also accumulates in soft tissue, the liver being the
largest storage site at 33 %, and is stored in the kidneys,
pancreas, ovaries, spleen, prostate, adrenal glands, brain,
fatty tissue, testicles, heart, and skeletal muscle. It appears
that lead concentrations in soft tissue remain similar
throughout one’s lifetime [42].
Other biomarkers of lead exposure
Lead bonds with sulfhydryl proteins via divalent cations,
thereby blocking protein structuration and enzyme action.
The most representative example of this is the blocking of
the action of the enzyme delta-aminolevulinic acid dehy-
dratase (delta-ALAD; ALAD) during the process of heme
synthesis. Impeding heme synthesis in this way is a major
part of the mechanism of lead’s pathology, and if blood
lead levels reach 20 μg/dL or higher, ALAD action is
reduced by 50 % or more. However, because ALAD is not
linearly related to the blood lead level, it is not utilized for
diagnosis of lead poison [43].
Due to the decrease in ALAD, there is an increase in
urinary aminolevulinic acid (ALA). As this phenomenon
occurs at a blood lead level of 35 μg/dL or higher in
adults and between 25 and 75 μg/dL in children, it
cannot be utilized as a useful indicator of low-level lead
poisoning. Blood ALA increases as blood ALAD de-
creases, and there appears to be a relation between the
behavioral problems observed in lead poisoning and
ALA’s reduction of gamma-Aminobutyric acid (GABA)
secretion in the central nervous system [44]. In addition,
the drop in heme synthesis leads to a drop in hemoglobin
synthesis, which affects cellular respiration, and in cases of
chronic lead exposure may cause fatigue and anemia. The
level of ALAD expression in humans is influenced by the
ALAD1 and ALAD2 genes, and studies have found that
the ALAD2 gene raises blood lead levels and sensitivity to
lead poisoning [45].
Ferrochelatase is an enzyme that inserts iron into pro-
toporphyrin IX. This process is inhibited by lead, result-
ing in an increase in erythrocyte protoporphyrin (EP)
and zinc protoporphyrin (ZPP). Due to such properties,
EP and ZPP are used in the diagnosis of lead poisoning.
However, the limitations of using EP and ZPP include
the fact that blood lead levels must reach 30 μg/dL or
greater in adults and 15 μg/dL in children for ZPP levels
to increase, as well as the fact that a decline in heme
synthesis is not limited to lead poisoning, and similar
results can be found in cases such as porphyria, normal
brain aging, hepatocirrhosis, and iron-deficiency [46].
Besides that, because lead lowers pyrimidine 5′-nucle-
otidase activity, blocking the maturation of red blood
cells and ultimately causing anemia, basophilic stippling
and hemolysis of immature red blood cells can be used
as biomarkers. While basophilic stippling and hemocyto-
lysis of immature red blood cells can occur from expos-
ure to substances like benzene or arsenic, microcytic or
normocytic-hypochromic anemia accompanied by baso-
philic stippling only occur in cases where the blood lead
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levels are 50 μg/dL in adults and 25–40 μg/dL or greater
in children [47].
Management of lead exposure: chelation
The majority of chelating agents bind to heavy metals in
extracellular fluid and cannot cross the cellular mem-
brane. Because they cause essential metal loss and may
cause adverse drug effects such as hepatotoxicity or
nephrotoxicity, while there are benefits to their use in
cases of acute poisoning, they are not recommended for
cases of chronic poisoning (Fig. 1) [48]. Due to the risk
caused by the adverse side effects of the medicine and
the redistribution of lead, chelation therapy is generally
not recommended in cases where blood lead levels are
below 45 μg/dL in adults [4]. Additionally, as rebounding
commonly occurs after chelation therapy, blood lead levels
should be measured before and after the treatment.
The drugs used as chelating agents for lead include
dimercaptosuccinic acid (DMSA), dimercaptopropane sul-
fonate (DMPS), dimercaprol (British Anti-Lewisite, BAL),
penicillamine, and CaNa2EDTA (Table 1).
An analogue of dimercaprol, DMSA is a dithiol com-
pound which contains two sulfhydryl (–SH) groups.
DMSA has a large therapeutic window, and is the least
toxic dithiol compound. While chelation therapy can
result in a reduction in essential metals, DMSA has been
found to not cause a reduction in essential metals such
as zinc, iron, calcium, and magnesium [49]. DMSA is
the most efficient and safe chelating agent for lead
exposure, so the chelators being used the most are
DMSA recently [50].
DMPS is another analogue of dimercaprol. Less effective
than CaNa2EDTA or DMSA, DMPS is not commonly
used in lead chelation therapy [48]. DMPS is mainly used
in cases of arsenic or mercury poisoning.
The drawbacks of CaNa2EDTA are that it contributes to
a greater loss in essential minerals compared to DMSA or
DMPS and that it redistributes lead to the brain [50].
Generally, one gram of EDTA is mixed with 250 mL of a
5 % dextrose solution, gradually settling over one or two
hours, and treatment is administered over a five day
period. During the treatment period, the patient should be
hydrated intravenously, and tests should be conducted
daily on kidney function, electrolyte levels, and urine.
Penicillamine was the first chelating agent used in
the treatment of lead poisoning. It reaches its greatest
capacity one to four hours after oral administration.
Food, antioxidants, and iron supplements can reduce
absorption of penicillamine. In the past, the daily dose
used was 500–1000 mg, but recent findings show that
using a lower dosage had equivalent lead removal effects
while reducing adverse side effects [51]. Due to the
narrow therapeutic window and harsh side effects of
dimercaprol (British Anti-Lewisite, BAL), it is rarely used
these days.
In general, chelation therapy is recommended for
children only in cases where blood lead levels are
45 μg/dL or greater. In cases where blood lead levels
are 45–69 μg/dL, chelation therapy can be attempted
with DMSA. McKay [52] tried chelation therapy on
children with blood lead levels of 20–44 μg/dL. While
the blood lead levels of the children who received chela-
tion therapy decreased temporarily compared with the
control group, when a follow-up study was conducted
three years later, the blood lead levels of the therapy group
had risen again, and no significant difference was observed
in cognitive or behavioral function nor in blood lead levels
between the therapy group and the control group.
While removing the source of lead exposure is most
important for reducing the health impact of lead and
similar harmful heavy metals, naturally occurring essen-
tial minerals (calcium, magnesium, selenium, etc.) and
other related nutrient replacement therapies can be use-
ful in decreasing the absorption of harmful heavy metals
Fig. 1 Benefits and drawbacks of chelation therapy
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or promoting their excretion. New strategies in heavy
metal chelation therapy include the use of structurally
different chelating agents (combination therapy such as
DMSA and EDTA) and the co-administration of antioxi-
dants such as DMSA and taurine [50].
Dietary management
Antioxidants are effective in alleviating and treating the
oxidative stress-induced toxicity of lead. By interacting
with generated reactive oxygen species (ROS), antioxi-
dants prevent radical chain reactions. By chelating with
lead ions, ROS generation is blocked, preventing and
alleviating lead’s toxicity. While chelating agents can re-
move lead from the body, their effectiveness in treating
lead’s neurological toxicity is unclear, and thus, they
are not used in treatment for children with low blood
lead concentrations [52]. Additionally, as chelating agents
have a rebound effect, they cannot be used in instances
where lead exposure cannot be suspended. However, anti-
oxidants can be used in such instances where lead expos-
ure cannot be suspended or in cases of low blood lead
levels [5]. Antioxidants used in the alleviation of lead
toxicity include vitamins, flavonoids, and herbs.
Vitamins
Vitamin B6 (pyridoxine) and B1 (thiamine) are effect-
ive in alleviating health problems caused by lead poi-
soning [5]. Vitamin B6 produces antioxidant effects by
promoting GSH generation. In an animal study using
rats as subjects, vitamin B1 was effective in alleviating
lead-induced lipid peroxidation [53]. Lee et al. [54] found
blood lead levels and homocysteine to have a proportional
relationship in adults in the U.S., but as this showed differ-
ent patterns depending on the vitamin B6, they suggested
that an appropriate concentration of B6 in the body be
maintained in order to block the effects of lead exposure.
Vitamin C (ascorbic acid) is the most widely studied
antioxidant capable of removing free radicals. Unsur-
passed in its ability to bind to and remove lead, vitamin C
is highly effective at alleviating lead toxicity [55]. Through
its antioxidant activity, vitamin C improves the lead-
induced impairments in synaptic plasticity. The combined
administration of vitamin C with silymarin can alleviate
lead-induced hepatotoxicity [56]. In a study by Tandon
et al. [57], lead-poisoned patients were administered
250 mg of vitamin C two times daily for a month, which
resulted in a reduction in blood lead levels and an increase
in blood ALAD activity. One study found that administer-
ing 250–500 mg of vitamin C daily to children was effect-
ive in removing free radicals and in treating lead-induced
health problems [58].
A fat-soluble vitamin, vitamin E (α-tocopherol) exhibits
powerful antioxidant effects. With its neuro-protective
effect and antioxidant effect, vitamin E improves cog-
nitive impairment caused by aging [59]. Sajitha et al.
[60] reported an improvement in lipid levels and the
alleviation of lipid peroxidation-induced liver, heart, and
kidney impairment in rats that had been administered
vitamin E. As vitamin E improves lead-induced memory
impairment, it has been recommended as good for pre-
venting lead-induced health problems with appropriate
dosing [61].
Table 1 Overview of chelation drugs
Chemical name (common names,
abbreviations)




10 mg/kg (or 350 mg/m2) per 8 h for
5 days, then 10 mg/kg per 12 h for
14 days (a total of 19 days), POa.
Gastrointestinal disturbances, mild
increase in serum transaminase
Lead, arsenic, mercury,




Adult: 5 mg/kg per 6–8 h, PO, IMb,
IVc, or SQd.
Low back (kidney) pain,
gastrointestinal disturbances, skin
rash, fatigue, hypersensitivity reactions
Mercury, arsenic, lead,
cadmium, tin, silver, copper,
selenium, zinc, magnesium






1000–1500 mg/m2/day (1–2 g/24 h
for a 70-kg adult) as an IV infusion
for 5 days
Renal toxicity Lead, cadmium, zinc
(2S)-2-amino-3-methyl-3-
sulfanylbutanoic acid (3-Sulfanyl-D-
valine; Penicillamine; D- Penicillamine)
10 mg/kg/day for 7 days with a
possibility of a prolonged treatment







(Dimercaprol; British Anti-Lewisite; BAL)
50–75 mg/m2 per 4 h for 5 days,
deep IM.
Allergy, gastrointestinal symptoms,
tachycardia, fever, elevation of liver
function tests
Arsenic, gold, mercury, lead
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Flavonoids
Natural polyphenolic compounds, flavonoids are abun-
dant in fruits and vegetables. Like other antioxidants,
flavonoids prevent oxidative stress by binding with heavy
metal ions and preventing free radical chain reactions.
Quercetin is abundant in fruit, vegetables, and tea. It has
a stronger antioxidant effect than vitamin C or E. Not
merely possessing antioxidant effects, quercetin also has
anti-inflammatory properties, and findings show that it
is effective for diseases such as ischemic heart disease,
atherosclerosis, hepatocirrhosis, and nephritis [62, 63].
Quercetin is effective in alleviating lead-induced liver,
kidney, and brain damage [64, 65]. In particular, as quer-
cetin crosses the blood-brain barrier, it can alleviate
toxicity in the brain by being able to bind to some of the
lead accumulated in the hippocampus [66]. Though the
optimal dosage has not been settled, the oral ingestion
of quercetin is known to cause no particular side effects
[64]. Therefore, with almost no adverse side effects,
being extremely effective at removing lead and treating
lead-induced toxicity, quercetin is a medicine worth
recommending when lead exposure is suspected.
An antioxidant that can be used in the treatment and
prevention of oxidative stress-induced disease, α-lipoic
acid is found in foods like carrots, beets, and potatoes.
While lipoid acid blocks oxidative stress, as it does not
chelate to heavy metals, it is often used in combination
with chelating agents, DMSA (2,3-dimercaptosuccinic
acid) in particular. According to previous studies, lipoic
acid used in combination with DMSA showed excellent
effectiveness in alleviating lead-induced oxidative stress
[67], as well as having similar effects in other heavy
metals (arsenic) besides lead [68]. Pande and Flora [69]
reported that a combination of lipoic acid and thiol che-
lator was able to alleviate lead toxicity, and in particular,
it reduced oxidative stress and lead levels in the brain.
Herbs
Inexpensive and with few adverse side effects, herbs are
being used clinically with effect. However, as the treatment
period is very long, their use is limited to prevention
rather than treatment of symptoms of lead exposure.
Garlic is mostly used for cooking, but due to its anti-
oxidant effect, it is also widely used as an antioxidant.
Garlic is effective in preventing lead-induced impairment
of the liver or reproductive organs [70]. In an investiga-
tion into the herbal intake and blood lead levels in U.S.
adults, Buettner et al. [71] found that, unlike with other
herbs, the blood lead level of adults who had ingested
garlic did not increase, and stated that this finding implies
the efficacy of garlic in controlling blood lead levels. In a
study where garlic and D-penicillamine were administered
over a period of four weeks to two groups of patients with
chronic lead poisoning, Kianoush et al. [72] reported that,
while blood lead levels were reduced in both groups, the
levels were lower in the garlic-administered group.
A substance from the spice derived from the rhizomes
of a plant known as curcuma longa, curcumin is a poly-
phenol compound. Sukla et al. [73] found via animal
studies that curcumin is effective in preventing lead-
induced neurotoxicity. Since those findings, many studies
have been carried out looking at curcumin and lead
toxicity.
Conclusions
Many studies have been conducted on the occupational
exposure and health impact of lead, and the various efforts
to prevent health problems caused by lead resulted in the
significant decrease in the number of cases of occupa-
tional lead poisoning. As interest has grown in lead’s car-
cinogenicity and the health problems of environmental
lead exposure and exposure to low concentrations of lead,
efforts are underway to reduce the concentrations of lead
in the environment. Recently, studies have been con-
ducted on health problems caused by low-level lead ex-
posure, and reports on long-term low-level lead exposure
and a variety of health problems are being continuously
published. In this study we examined the toxicity and
health impact of lead, and reviewed recent literature on
the observation and treatment of lead exposure. We
expect that this study can be usefully applied to the obser-
vation and management of environmental lead exposure.
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